<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Management | Management | Allergic rhinitis | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the management and referral of children and adults with allergic rhinitis in primary care."/><meta data-react-helmet="true" property="og:description" content="Covers the management and referral of children and adults with allergic rhinitis in primary care."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/allergic-rhinitis/management/management/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Management | Management | Allergic rhinitis | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/allergic-rhinitis/management/management/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Allergic rhinitis</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Management</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/allergic-rhinitis/","name":"Allergic rhinitis"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/allergic-rhinitis/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Management"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Allergic rhinitis: </span><span>Scenario: Management</span></h1><p class="page-header__lead"><span>Last revised in September 2018</span></p></div><p class="visually-hidden">Covers the management and referral of children and adults with allergic rhinitis in primary care.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Allergic rhinitis chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Diagnosis"><a aria-current="false" href="../../diagnosis/index.html"><span class="stacked-nav__content-wrapper">Diagnosis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Management</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Prescribing information"><a aria-current="false" href="../../prescribing-information/index.html"><span class="stacked-nav__content-wrapper">Prescribing information</span></a></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#self-management-strategies">Self-management strategies</a><ol aria-label="Sections within Self-management strategies" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-b07">Basis for recommendation</a></li></ol></li><li><a href="index.html#initial-drug-treatment">Initial drug treatment</a><ol aria-label="Sections within Initial drug treatment" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-dfc">Basis for recommendation</a></li></ol></li><li><a href="index.html#treatment-failure-referral">Treatment failure and referral</a><ol aria-label="Sections within Treatment failure and referral" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#allergy-testing">Allergy testing</a></li><li class=""><a href="index.html#immunotherapy-treatment">Immunotherapy treatment</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-f2d">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="management" class="ChapterBody-module--wrapper--2HCfk "><h2 id="management" class="visually-hidden">Scenario: Management</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4393266c-d867-4b0b-85f7-0cf0f5201e66 --><!-- begin field 128066f3-7f69-47cd-8910-acbc0157e415 --><p>From age 24 months onwards.</p><!-- end field 128066f3-7f69-47cd-8910-acbc0157e415 --><!-- end item 4393266c-d867-4b0b-85f7-0cf0f5201e66 --></div><section aria-labelledby="self-management-strategies" class="ChapterBody-module--wrapper--2HCfk "><h3 id="self-management-strategies">What self-management strategies should I advise?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 97778796-463b-4139-986a-c00999df5911 --><!-- begin field 02b5656f-dab8-4e4c-b5ab-3064d1ee568b --><p><strong>If a person has a <a class="topic-reference internal-reference" href="../../diagnosis/diagnosis/index.html">diagnosis</a> of allergic rhinitis:</strong></p><ul><li><strong>Provide advice on sources of information and support, such as:</strong><ul><li>The Allergy UK factsheets on <a data-hyperlink-id="8f1be765-23c0-4258-b52e-a9650095cf35" href="https://www.allergyuk.org/information-and-advice/conditions-and-symptoms/11-hay-fever-allergic-rhinitis" target="_blank">Hay fever (Allergic Rhinitis)</a> and <a data-hyperlink-id="4e4bf4fa-61b9-4905-bae9-a965016046ef" href="https://www.allergyuk.org/information-and-advice/conditions-and-symptoms/320-improving-your-indoor-air-quality" target="_blank">Improving your indoor air quality</a>.</li><li>The NHS patient information leaflets <a data-hyperlink-id="239e4418-6945-4034-9d60-a9650095cf74" href="https://www.nhs.uk/conditions/allergic-rhinitis/" target="_blank">Allergic rhinitis</a> and <a data-hyperlink-id="3f8e68f8-9330-433a-8236-a9650095cf83" href="https://www.nhs.uk/conditions/hay-fever/" target="_blank">Hay fever</a>.</li><li>The patient information leaflet <a data-hyperlink-id="2a398e87-6e64-4b8c-8d66-a9650095cf91" href="https://patient.info/health/hay-fever-leaflet" target="_blank">Hay Fever and Seasonal Allergies</a> available on the <a data-hyperlink-id="225c538f-4716-4e57-b51d-a9650095cf99" href="https://patient.info/" target="_blank">www.patient.info</a> website.</li></ul></li><li><strong>Advise the person to consider the use of nasal irrigation with saline</strong> to rinse the nasal cavity using a spray, pump, or squirt bottle, which can be bought over-the-counter.</li><li><strong>Provide advice on allergen avoidance techniques</strong> if there is a specific identified <a class="topic-reference internal-reference" href="../../background-information/causes/index.html">causative allergen</a>:<ul><li><strong>For people with grass pollen allergy,</strong> advise to:<ul><li>Avoid walking in grassy, open spaces, particularly during the early morning, early evening, and during mowing, when the pollen count is high.</li><li>Avoid drying washing outdoors when the pollen count is high.</li><li>Keep windows shut in cars and buildings.</li><li>Plan holidays to avoid the pollen season, where possible.</li><li>Shower or wash hair following high pollen exposures.</li></ul></li><li><strong>For people with confirmed house dust mite allergy</strong> following <a class="topic-reference internal-reference" href="index.html#allergy-testing">allergy testing</a>, advise to:<ul><li><em>Not</em> fit mattresses, pillows, and duvets with house dust mite impermeable covers.</li><li>Use synthetic pillows and acrylic duvets, and keep furry toys off the bed.</li><li>Wash all bedding and furry toys at least once a week at high temperatures.</li><li>Choose wooden or hard floor surfaces instead of carpets, if possible.</li><li>Fit blinds that can be wiped clean instead of curtains. Surfaces should be wiped regularly with a clean, damp cloth.</li></ul></li><li><strong>For people with confirmed animal allergy</strong> following <a class="topic-reference internal-reference" href="index.html#allergy-testing">allergy testing</a>, advise to:<ul><li>Ideally not allow the animal in the house. If this is not acceptable or possible, advise restricting their presence to the kitchen.</li><li>Wash the animal and any surfaces they are in contact with, regularly.</li></ul></li><li><strong>For people with occupational allergy, </strong>advise to:<ul><li>Eliminate or reduce exposure to sensitizing allergens in the workplace, for example, by using latex-free gloves, wearing protective clothing, or a dust mask.</li><li>Ensure that their work environment is adequately ventilated and/or relocating to lower exposure areas in the workplace.</li><li>Use less hazardous chemicals, if possible and appropriate.</li></ul></li></ul></li></ul><!-- end field 02b5656f-dab8-4e4c-b5ab-3064d1ee568b --><!-- end item 97778796-463b-4139-986a-c00999df5911 --></div><section aria-labelledby="basis-for-recommendation-b07" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-b07">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b0783f66-0828-4770-b45a-e35fda42643b --><!-- begin field 01720ec8-c94e-466f-acd5-d749a857fde8 --><p>The recommendations on self-management strategies are largely based on the Allergic Rhinitis and its Impact on Asthma (ARIA) international guidelines (2010 revision) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>], expert opinion in the British Society of Allergy and Clinical Immunology guideline <em>BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>], a primary care expert consensus statement [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>], the European Academy of Allergy and Clinical Immunology position paper <em>Paediatric rhinitis</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>], the Cochrane systematic reviews <em>House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Nurmatov, 2012</a>] and <em>Saline irrigation for allergic rhinitis</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Head, 2018</a>], and expert opinion in review articles on allergic rhinitis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Saleh, 2007</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Barr, 2014</a>] and occupational rhinitis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Stevens, 2015</a>].</p><h5>Advice on nasal saline irrigation</h5><ul><li>The recommendation on considering nasal irrigation with saline is based on limited evidence in the literature that it may provide some symptom relief, and is unlikely to cause significant harm.<ul><li>The BSACI guideline notes that saline irrigation in children and adults is well tolerated, inexpensive, easy to use, and is unlikely to cause adverse effects. It has a small beneficial effect in symptom reduction and may reduce the need for subsequent drug treatment. In addition, it is a safe and effective option in pregnancy and while breastfeeding [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>].</li><li>This approach is supported by a primary care expert consensus statement, which found nasal irrigation to be a safe, inexpensive treatment which may reduce seasonal rhinitis symptoms in children and adults. It concluded, however, that it has a limited role in the management of allergic rhinitis, and there are limited data to support its use [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>].</li><li>A Cochrane systematic review of 14 randomized controlled trials (RCTs, n = 747) compared the effect of saline nasal irrigation with isotonic or hypertonic solution, with no irrigation or other drug treatments (intranasal corticosteroids or oral antihistamines) for children and adults with allergic rhinitis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Head, 2018</a>].<ul><li>It found low-quality evidence that saline irrigation may improve patient‐reported disease severity compared with no irrigation at up to three months, with no reported adverse effects. It is uncertain if saline irrigation in addition to drug treatment improved patient-reported disease severity compared with drug treatment alone at up to three months (very low-quality evidence).</li><li>It concluded that the included studies were generally small, and used different outcome measures, however, saline irrigation may provide a cheap, safe and acceptable alternative to some drug treatments in the management of allergic rhinitis.</li></ul></li><li>A review article found some evidence from small trials that saline irrigation improves mucociliary function, reduces mucosal oedema, and decreases inflammatory mediators in allergic rhinitis. It recommended its use in children to reduce symptoms and potentially reduce the need for drug treatment [<a class="bibliography-reference internal-reference" href="../../references/index.html">Barr, 2014</a>]. This approach is supported by the European position paper, which states saline irrigation may be a useful add-on treatment [<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>].</li></ul></li></ul><h5>Advice on grass pollen allergen avoidance</h5><ul><li>The recommendations on grass pollen avoidance are largely pragmatic based on very limited evidence, but are recommended in the BSACI guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>]. They are also supported by the expert opinion of previous external reviewers of this CKS topic.</li></ul><h5>Advice on house dust mite allergen avoidance</h5><ul><li>The 2010 revision of the ARIA guideline does not recommend the use of single chemical or physical preventative methods to reduce exposure to house dust mites, based on low-quality evidence [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>]. Similarly, the BSACI guideline does not recommend house dust mite avoidance measures such as encasing mattresses, pilllows, and duvets in allergen-impermeable fabric as a single intervention [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>].<ul><li>This is supported by a Cochrane systematic review of nine RCTs (n = 501) of bedroom environmental house dust mite control measures (including impermeable bedding covers, acaricides, and air filters) compared with placebo or other control measures [<a class="bibliography-reference internal-reference" href="../../references/index.html">Nurmatov, 2012</a>].<ul><li>It found that house dust mite impermeable bedding as an isolated intervention is unlikely to offer benefit. Other interventions may reduce house dust mite load, but this is based on limited evidence, as trials are generally small and of poor methodological quality, with heterogeneity of study design, and differing outcome measures, such that meta-analysis could not be performed.</li></ul></li></ul></li><li>The additional allergen avoidance measures are based on expert opinion in a review article on perennial rhinitis, which also recommends confirmation of house dust mite allergy by skin prick testing prior to the implementation of these potentially burdensome measures [<a class="bibliography-reference internal-reference" href="../../references/index.html">Saleh, 2007</a>].</li></ul><h5>Advice on animal dander allergen avoidance</h5><ul><li>The 2010 revision of the ARIA guideline strongly recommends people with allergic rhinitis caused by animal dander should avoid exposure to these allergens at home, based on very low-quality evidence [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>]. This approach is supported by the European position paper [<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>] and expert opinion in a review article that affected people should be discouraged from having pets in the home [<a class="bibliography-reference internal-reference" href="../../references/index.html">Saleh, 2007</a>].</li><li>Expert opinion in an additional review article recommends animals should be washed regularly, as should all surfaces in potential contact with animal dander [<a class="bibliography-reference internal-reference" href="../../references/index.html">Barr, 2014</a>].</li></ul><h5>Advice on occupational allergen avoidance</h5><ul><li>The recommendations on avoidance of occupational allergens is important, as symptoms may be reversible with early diagnosis and avoidance, but may become chronic and irreversible over time [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>].</li><li>The BSACI guideline recommends complete avoidance of exposure to causal agents in cases of occupational allergic rhinitis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>]. CKS notes that the 2010 revision of the ARIA guideline recommends immediate and total cessation of exposure to occupational allergen(s) in people with occupational rhinitis <em>and</em> asthma, based on very low-quality evidence, but does not make specific recommendations for people with occupational rhinitis alone [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>].</li><li>The specific recommendations on reducing workplace exposures are based on expert opinion in a review article, which notes that occupational rhinitis may be a predictor for the future development of occupational asthma [<a class="bibliography-reference internal-reference" href="../../references/index.html">Stevens, 2015</a>]. Optimal management of occupational rhinitis may, therefore, help prevent progression to occupational asthma.</li></ul><!-- end field 01720ec8-c94e-466f-acd5-d749a857fde8 --><!-- end item b0783f66-0828-4770-b45a-e35fda42643b --></div></section></section><section aria-labelledby="initial-drug-treatment" class="ChapterBody-module--wrapper--2HCfk "><h3 id="initial-drug-treatment">What initial drug treatments should I recommend?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4518d804-7090-43a2-965d-5fcb177a1e03 --><!-- begin field 944eeaae-c61d-464c-83f4-68d4bbf75005 --><p><strong>If a person has a <a class="topic-reference internal-reference" href="../../diagnosis/diagnosis/index.html">diagnosis</a> of allergic rhinitis, advise on <a class="topic-reference internal-reference" href="index.html#self-management-strategies">self-management strategies</a> and drug treatment options:</strong></p><ul><li><strong>If the person has mild-to-moderate intermittent, or mild persistent symptoms:</strong><ul><li>Advise on the 'as-needed' use of an intranasal antihistamine first-line, or a second-generation, non-sedating oral antihistamine, depending on the person's age and personal preference.<ul><li>Advise that intranasal antihistamines (azelastine) have a faster onset of action and are more effective than oral preparations. See the section on <a class="topic-reference internal-reference" href="../../prescribing-information/intranasal-antihistamines/index.html">Intranasal antihistamines</a> in <a class="topic-reference internal-reference" href="../../prescribing-information/index.html">Prescribing information</a> for more information on intranasal antihistamines and intranasal <a class="topic-reference internal-reference" href="../../prescribing-information/intranasal-antihistamines/index.html#intranasal-spray-drop-technique">spray and drop technique</a>.</li><li>Oral antihistamine options include loratadine or cetirizine, which may be available over-the-counter. See the section on <a class="topic-reference internal-reference" href="../../prescribing-information/oral-antihistamines/index.html">Oral antihistamines</a> in <a class="topic-reference internal-reference" href="../../prescribing-information/index.html">Prescribing information</a> for more information.</li></ul></li><li>Consider the use of an intranasal chromone such as sodium cromoglicate to be used 'as needed', if antihistamines are contraindicated or not tolerated.<ul><li>Advise that these preparations need to be used up to four times a day. See the section on <a class="topic-reference internal-reference" href="../../prescribing-information/intranasal-cromones/index.html">Intranasal cromones</a> in <a class="topic-reference internal-reference" href="../../prescribing-information/index.html">Prescribing information</a> for more information.</li></ul></li></ul></li><li><strong>If the person has moderate-to-severe persistent symptoms, or initial drug treatment is ineffective:</strong><ul><li>Prescribe a regular intranasal corticosteroid to be used during periods of allergen exposure.<ul><li>Options include intranasal mometasone furoate, fluticasone furoate, or fluticasone propionate. See the CKS topic on <a class="topic-reference external-reference" href="../../../corticosteroids-topical-skin-nose-eyes/index.html">Corticosteroids - topical (skin), nose, and eyes</a> for more prescribing information including different preparations and advice on intranasal spray and drop technique.</li><li>Advise the person that the onset of action is 6–8 hours after the first dose, but the maximal effect may not be seen until after two weeks.</li><li>Nasal drops may be preferred if there is severe nasal obstruction.</li><li>Advise the person not to increase beyond the prescribed dose as there is no evidence of additional benefit, and do not switch to an alternative preparation, as they all have comparable efficacy.</li></ul></li></ul></li><li><strong>If drug treatment provides adequate symptom control, advise the person to continue treatment until they are no longer likely to be exposed to the suspected allergen.</strong> For people allergic to:<ul><li>House dust mite and/or pets in the home — symptoms are usually present throughout the year, requiring ongoing treatment.</li><li>Tree pollens — treatment is usually required from early to late spring.</li><li>Grass pollens — treatment is usually required from late spring to early summer.</li><li>Weed pollens — treatment is usually required from early spring to late autumn.<ul><li>If there are recurrent episodes of symptoms controlled by intranasal corticosteroids, advise the person to restart treatment two weeks before re-exposure to causative allergens.</li><li>If the time of re-exposure is uncertain, such as the start of the pollination season, advise the person to start treatment several weeks before the most likely time of re-exposure.</li></ul></li></ul></li><li><strong>Advise the person to be reviewed after 2–4 weeks</strong> if symptoms persist after initial treatment, as management may need to be stepped up. See the section on <a class="topic-reference internal-reference" href="index.html#treatment-failure-referral">Treatment failure and referral</a> for more information.</li></ul><!-- end field 944eeaae-c61d-464c-83f4-68d4bbf75005 --><!-- end item 4518d804-7090-43a2-965d-5fcb177a1e03 --></div><section aria-labelledby="basis-for-recommendation-dfc" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-dfc">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item dfc235cc-28c1-4d4f-821f-93faaf88bd45 --><!-- begin field fcb330c1-d690-45f6-ae2a-60f736e30e1d --><p>The recommendations on initial drug treatment of allergic rhinitis are largely based on the Allergic Rhinitis and its Impact on Asthma (ARIA) international guidelines 2008 publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">ARIA, 2008</a>], 2010 revision [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>], and 2016 revision [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek, 2017</a>]; expert opinion in the British Society of Allergy and Clinical Immunology guideline <em>BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>], a primary care expert consensus statement <em>An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>], the European Academy of Allergy and Clinical Immunology position paper <em>Paediatric rhinitis</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>], and expert opinion in a review article on allergic rhinitis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Barr, 2014</a>].</p><h5>Managing mild-to-moderate intermittent, or mild persistent symptoms</h5><ul><li>The recommendations on the first-line management of allergic rhinitis with an intranasal (or oral) antihistamine are largely based on the 2010 revision of the ARIA international guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>], the BSACI guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>], the European position paper [<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>], and an expert consensus statement [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>].<ul><li>The therapeutic effect of intranasal antihistamines is generally superior to oral preparations in reducing rhinitis symptoms and nasal obstruction, and they have a faster onset of action for controlling breakthrough symptoms [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>].</li><li>CKS notes that the 2016 revision of the ARIA international guideline recommends the use of either intranasal or oral antihistamines for seasonal and persistent rhinitis symptoms, based on low-quality evidence, and states the choice of treatment will depend on personal preference, local availability, and cost. If oral antihistamines are being considered, the 2010 revision recommends the use of new generation non-sedating oral antihistamines first-line.</li></ul></li><li>The recommendation on the use of cromones such as sodium cromoglicate is based on the 2010 revision of the ARIA guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>], the BSACI guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>], and the European position paper [<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>].<ul><li>The ARIA guideline recommends intranasal cromones on the basis of moderate-quality evidence, however, it notes that the need to apply the preparation four times a day is likely to reduce adherence with treatment and thereby reduce efficacy. It also notes these preparations are likely to be less effective than intranasal anthistamines.</li><li>The BSACI guideline states these agents may be used for people with mild, intermittent symptoms or with limited allergen exposure. It notes cromones may be weakly effective for rhinitis symptoms with some effect on nasal obstruction, and may be particularly useful for people with limited drug treatment options, such as pregnant or breastfeeding women.</li><li>The European position paper notes that intranasal sodium cromoglicate may be an effective treatment based on old studies, but the need for frequent application may reduce concordance.</li></ul></li><li>The recommendation to educate the person on the correct intranasal spray or drop technique is based on the fact that treatment failure may be related to incorrect administration technique [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>].</li></ul><h5>Managing moderate-to-severe persistent symptoms, or non-response to initial treatment</h5><ul><li>The recommendation to prescribe intranasal corticosteroids regularly first-line for moderate-to-severe disease is based on evidence-based recommendations in the ARIA international guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek, 2017</a>], expert opinion in the BSACI guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>], and the European position paper [<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>].<ul><li>The 2010 revision of the ARIA guideline recommends intranasal corticosteroids for the treatment of allergic rhinitis in children and adults, based on high-quality and moderate-quality evidence respectively. It also notes these preparations are more effective than oral antihistamines in children and adults with seasonal and persistent symptoms. The BSACI guideline also states that meta-analysis found intranasal corticosteroids to be superior to oral antihistamines.</li><li>The 2016 revision of the ARIA guideline notes that intranasal corticosteroid monotherapy provides a greater reduction in seasonal and persistent symptoms than intranasal antihistamine monotherapy, based on moderate- and low-quality evidence respectively.</li></ul></li><li>The recommendations on the choice of intranasal corticosteroid preparations are based on expert opinion in the BSACI guideline and in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Barr, 2014</a>], as these formulations have negligible systemic absorption, reducing the likelihood of adverse effects.</li><li>The recommendations on the onset of action and the use of intranasal drops for severe obstruction are based on expert opinion in the BSACI guideline.</li><li>The recommendations not to increase the dose of intranasal corticosteroid as there is a recognised ceiling effect, and not to switch preparations as they all have comparable efficacy, are based on expert opinion in a consensus statement [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>].</li></ul><h5>Advice on durations of drug treatment</h5><ul><li>The information on the timings of likely exposure to causative allergens is extrapolated from information in the 2008 ARIA international guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">ARIA, 2008</a>].</li><li>The recommendation to start intranasal corticosteroids two weeks prior to a known allergen season is based on the fact that the maximal effect of intranasal corticosteroids may not be seen until two weeks after starting treatment [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>].</li></ul><h5>Arranging review if symptoms persist</h5><ul><li>The recommendation to arrange review if symptoms persist after 2–4 weeks is based on an expert consensus statement, which considers a two-week trial appropriate to assess initial response to antihistamines, and a four-week trial appropriate for intranasal corticosteroids [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>].</li></ul><!-- end field fcb330c1-d690-45f6-ae2a-60f736e30e1d --><!-- end item dfc235cc-28c1-4d4f-821f-93faaf88bd45 --></div></section></section><section aria-labelledby="treatment-failure-referral" class="ChapterBody-module--wrapper--2HCfk "><h3 id="treatment-failure-referral">How should I manage treatment failure?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5f32c92e-104b-46d9-9b50-f69846e0243d --><!-- begin field ff1d1526-4961-406e-b361-473e249988ff --><p><strong>If a person has uncontrolled symptoms following initial <a class="topic-reference internal-reference" href="index.html#self-management-strategies">self-management strategies</a> and <a class="topic-reference internal-reference" href="index.html#initial-drug-treatment">drug treatment</a>:</strong></p><ul><li><strong>Consider causes for treatment failure.</strong><ul><li>Check compliance with self-management strategies, if appropriate.</li><li>Check compliance with initial drug treatments and/or the <a class="topic-reference internal-reference" href="../../prescribing-information/intranasal-antihistamines/index.html#intranasal-spray-drop-technique">correct technique</a> when using intranasal sprays or drops.</li><li>An <a class="topic-reference internal-reference" href="../../diagnosis/differential-diagnosis/index.html">alternative diagnosis</a> or non-allergic cause for symptoms.</li></ul></li><li><strong>Consider stepping up treatment</strong> if a person has refractory symptoms while using a regular intranasal corticosteroid preparation.<ul><li>If nasal congestion is a problem, add in a short-term intranasal decongestant such as ephedrine or xylometazoline for up to 5–7 days, depending on the person's age and preparation used.<ul><li>See the section on <a class="topic-reference internal-reference" href="../../prescribing-information/intranasal-decongestants/index.html">Intranasal decongestants</a> in <a class="topic-reference internal-reference" href="../../prescribing-information/index.html">Prescribing information</a> for more information.</li></ul></li><li>If there is persistent watery rhinorrhoea despite combined use of an intranasal corticosteroid and oral antihistamine, add in an intranasal anticholinergic such as ipratropium bromide.<ul><li>See the section on <a class="topic-reference internal-reference" href="../../prescribing-information/intranasal-anticholinergics/index.html">Intranasal anticholinergics</a> in <a class="topic-reference internal-reference" href="../../prescribing-information/index.html">Prescribing information</a> for more information.</li></ul></li><li>If there is persistent nasal itching and sneezing, options are to add in an oral antihistamine to be used regularly rather than 'as needed', or to prescribe a combination preparation containing an intranasal antihistamine (azelastine) and intranasal corticosteroid (fluticasone propionate) such as Dymista<sup>®</sup> spray, if monotherapy with either an antihistamine or intranasal corticosteroid is ineffective.<ul><li>See the sections on <a class="topic-reference internal-reference" href="../../prescribing-information/oral-antihistamines/index.html">Oral antihistamines</a> and <a class="topic-reference internal-reference" href="../../prescribing-information/intranasal-antihistamines/index.html">Intranasal antihistamines</a> in <a class="topic-reference internal-reference" href="../../prescribing-information/index.html">Prescribing information</a>, and the CKS topic on <a class="topic-reference external-reference" href="../../../corticosteroids-topical-skin-nose-eyes/index.html">Corticosteroids - topical (skin), nose, and eyes</a> for more information.</li><li>Note: combined use of an intranasal <em>and</em> oral antihistamine is not recommended.</li></ul></li><li>If the person has ongoing symptoms and a history of asthma, consider adding in a leukotriene receptor antagonist such as montelukast to an oral or intranasal antihistamine.<ul><li>See the section on <a class="topic-reference internal-reference" href="../../prescribing-information/oral-leukotriene-receptor-antagonists/index.html">Oral leukotriene receptor antagonists</a> in <a class="topic-reference internal-reference" href="../../prescribing-information/index.html">Prescribing information</a> for more information.</li></ul></li></ul></li><li><strong>If the person has severe, uncontrolled symptoms that are significantly affecting quality of life, consider prescribing a short course of oral corticosteroids</strong> to provide rapid symptom relief, such as:<ul><li>For adults — prednisolone 0.5 mg/kg in the morning for 5–10 days.</li><li>For children — prednisolone 10–15 mg in the morning for 3–7 days.<ul><li>Advise the person to continue using an intranasal corticosteroid preparation, to allow improved intranasal drug penetration.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../corticosteroids-oral/index.html">Corticosteroids - oral</a> for more prescribing information.</li></ul></li></ul></li><li><strong>If drug treatment provides adequate symptom control, advise the person to continue treatment until they are no longer likely to be exposed to the suspected allergen.</strong> For people allergic to:<ul><li>House dust mite and/or pets in the home — symptoms are usually present throughout the year, requiring ongoing treatment.</li><li>Tree pollens — treatment is usually required from early to late spring.</li><li>Grass pollens — treatment is usually required from late spring to early summer.</li><li>Weed pollens — treatment is usually required from early spring to late autumn.<ul><li>If there are recurrent episodes of symptoms controlled by intranasal corticosteroids, advise the person to restart treatment two weeks before re-exposure to causative allergens.</li><li>If the time of re-exposure is uncertain, such as the start of the pollination season, advise the person to start treatment several weeks before the most likely time of re-exposure.</li></ul></li></ul></li><li><strong>Consider arranging referral for specialist assessment and management to an allergy or ear, nose, and throat (ENT) specialist if:</strong><ul><li>There are red flag features such as unilateral symptoms, blood-stained nasal discharge, recurrent epistaxis, or nasal pain — arrange an urgent two-week wait referral to ENT.</li><li>There is predominant nasal obstruction and/or a structural abnormality such as deviated nasal septum which makes intranasal drug treatment difficult — arrange referral to ENT.</li><li>There are persistent symptoms despite optimal management in primary care — consider referral to an allergy specialist for <a class="topic-reference internal-reference" href="index.html#allergy-testing">allergy testing</a> and possible <a class="topic-reference internal-reference" href="index.html#immunotherapy-treatment">immunotherapy treatment</a>, depending on local referral pathways and availability.</li><li><a class="topic-reference internal-reference" href="index.html#self-management-strategies">Allergen avoidance techniques</a> such as house dust mite or animal dander avoidance are being considered — skin prick <a class="topic-reference internal-reference" href="index.html#allergy-testing">allergy testing</a> to confirm the responsible allergen may be needed.</li><li>The diagnosis is uncertain — consider referral to an allergy or ENT specialist, depending on clinical judgement.</li></ul></li></ul><!-- end field ff1d1526-4961-406e-b361-473e249988ff --><!-- end item 5f32c92e-104b-46d9-9b50-f69846e0243d --></div><section aria-labelledby="allergy-testing" class="ChapterBody-module--wrapper--2HCfk "><h4 id="allergy-testing">Allergy testing</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5c8c2593-2f2c-4e1c-a222-a96600c12162 --><!-- begin field b73755bc-5ff6-420e-80f5-a96600c121c2 --><ul><li><strong>Allergy testing may involve skin prick testing or measuring the levels of serum-specific immunoglobulin (Ig) E to allergens such as house dust mites, pollen, and animal dander (radioallergosorbent test [RAST]).</strong><ul><li>Skin prick testing may help to differentiate between allergic and non-allergic rhinitis, and has a high negative predictive value. It has a better positive predictive value than serum testing, and provides immediate results, however results may be suppressed by recent antihistamine, tricyclic antidepressant (TCA), and topical corticosteroid use. Interestingly, at least 15% of people with a positive skin prick test do not develop symptoms on exposure to the relevant allergen, and therefore positive tests alone do not confirm the causative allergen if there is no supportive history.</li><li>Serum testing may be used when skin prick testing is not possible, or skin prick testing taken with the clinical history give equivocal results.</li></ul></li></ul><p>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Barr, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>] </p><!-- end field b73755bc-5ff6-420e-80f5-a96600c121c2 --><!-- end item 5c8c2593-2f2c-4e1c-a222-a96600c12162 --></div></section><section aria-labelledby="immunotherapy-treatment" class="ChapterBody-module--wrapper--2HCfk "><h4 id="immunotherapy-treatment">Immunotherapy treatment</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d5ae8fba-1747-41aa-bb9e-a96600c15cd4 --><!-- begin field d36e74ab-3894-46a0-87c4-a96600c15e53 --><ul><li><strong>Specialist immunotherapy may be appropriate for people with symptoms on allergen exposure, objective confirmation of IgE sensitivity, and persistent symptoms</strong> predominantly due to one allergen such as grass pollen or house dust mite. Treatment may be by subcutaneous injection or sublingual, and involves exposing the person to increasing amounts of allergen to induce clinical and immunological tolerance.<ul><li>Subcutaneous therapy may involve weekly initial dosing regimens followed by 4–6 weekly maintenance injections usually for 3 years. Pre-seasonal immunotherapy may be effective for pollen allergy.</li><li>Sublingual immunotherapy may be an alternative for the treatment of allergic rhinitis due to one or more species of grass pollen and house dust mite. If tolerated, subsequent doses may be self-administered daily at home for, usually, 3 years.<ul><li>Adverse effects are generally short-lived: subcutaneous immunotherapy may cause itching, redness, and swelling at the injection site; sublingual immunotherapy may cause oropharyngeal itching and localized swelling which typically settles with repeated dosing.</li><li>Immunotherapy is the only treatment that can modify disease progression, with long-term remission possible following the end of treatment. Subcutaneous immunotherapy in children with seasonal rhinitis may reduce the risk of progression to asthma, and may prevent the development of new sensitizations.</li></ul></li></ul></li></ul><p>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Barr, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Slovick, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>]</p><!-- end field d36e74ab-3894-46a0-87c4-a96600c15e53 --><!-- end item d5ae8fba-1747-41aa-bb9e-a96600c15cd4 --></div></section><section aria-labelledby="basis-for-recommendation-f2d" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-f2d">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f2d59e43-7d9e-486b-a7c8-ba015468d97c --><!-- begin field 6e38b8aa-27a0-4de5-a606-6586514e41c2 --><p>The recommendations on treatment failure and referral are largely based on the Allergic Rhinitis and its Impact on Asthma (ARIA) international guidelines 2008 publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">ARIA, 2008</a>], 2010 revision [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>], and 2016 revision [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek, 2017</a>], expert opinion in the British Society of Allergy and Clinical Immunology guideline <em>BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>], a primary care expert consensus statement <em>An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>], the European Academy of Allergy and Clinical Immunology position paper <em>Paediatric rhinitis</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>], and expert opinion in review articles on allergic rhinitis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Saleh, 2007</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Barr, 2014</a>].</p><h5>Managing potential causes of treatment failure</h5><ul><li>The information on potential causes of treatment failure are based on expert opinion in the BSACI guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>] and an expert consensus statement [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>].</li></ul><h5>Adding in a short-term intranasal decongestant</h5><ul><li>The recommendation to use a short-term intranasal decongestant is largely based on the 2010 revision of the ARIA international guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>], expert opinion in the BSACI guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>] and in the European position paper [<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>].<ul><li>The ARIA guideline recommends very short-term use of an intranasal decongestant for up to five days in adults with severe nasal obstruction, based on very low-quality evidence [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>].</li><li>CKS notes that the British National Formulary (BNF) recommends the use of intranasal decongestants for 5–7 days, depending on the age of the person and the preparation used, in order to minimize the risk of rebound congestion and rhinitis medicamentosa associated with longer term use [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 76, 2018</a>]. CKS also notes that the BSACI guideline recommends use of an intranasal decongestant for less than 10 days, and the European position paper recommends use for a 'few days' for severe nasal obstruction.</li><li>The BSACI guideline notes these agents may relieve nasal congestion symptoms faster and more effectively than intranasal corticosteroids. They may also allow the delivery of intranasal preparations beyond the inferior turbinates, thereby improving other intranasal drug efficacy.</li></ul></li></ul><h5>Adding in an intranasal anticholinergic</h5><ul><li>The recommendation to use an intranasal anticholinergic agent such as ipratropium bromide is based on expert opinion in the European position paper [<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>] and the BSACI guideline, which states that these agents may have an 'add-on' role if watery rhinorrhoea persists despite treatment with intranasal corticosteroids and antihistamines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>].</li><li>This approach is supported by the 2010 revision of the ARIA international guideline, which recommends intranasal ipratropium bromide for the treatment of rhinorrhoea, based on moderate-quality evidence [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>], and also by a UK expert consensus statement [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>].</li></ul><h5>Adding in an oral antihistamine</h5><ul><li>The recommendation to consider adding in an oral antihistamine to an intranasal corticosteroid is extrapolated from the 2016 revision of the ARIA international guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek, 2017</a>], expert opinion in the BSACI guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>] and an expert consensus statement [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>].<ul><li>The ARIA guideline suggests this combination may be considered if there are moderate-to-severe intermittent symptoms which are not well controlled with intranasal corticosteroid monotherapy, based on low-quality evidence. It stresses the oral antihistamine should be used regularly rather than 'as needed', and this is supported by the BSACI guideline.</li></ul></li><li>The recommendation not to use both an intranasal and oral antihistamine is based on the BSACI guideline, which states that there is no additional advantage in using both agents together for rhinitis symptoms.</li></ul><h5>Prescribing a combination intranasal antihistamine and corticosteroid preparation</h5><ul><li>The recommendation to consider the use of a combination intranasal antihistamine and corticosteroid for refractory symptoms is based on the 2016 revision of the ARIA international guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek, 2017</a>], the BSACI guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>], and an expert consensus statement [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>].<ul><li>The ARIA guideline recommends the option of combination treatment, particularly as this may act faster than intranasal corticosteroid monotherapy, based on low- to moderate-quality evidence. It also notes that this combination is more effective for symptom reduction than the use of intranasal antihistamine monotherapy, based on low-quality evidence.</li><li>The BSACI guideline and expert consensus statement also recommend considering combination therapy second-line (prescribed as Dymista<sup>®</sup> intranasal spray) if the person is more than 12 years old with moderate or severe seasonal or persistent symptoms if monotherapy with either agent is not effective. In addition, the BSACI guideline suggests concordance with treatment may be higher when the drug regimen is simple, and it found combination therapy is more effective than using either agent alone.</li></ul></li></ul><h5>Adding in an oral leukotriene receptor antagonist</h5><ul><li>The recommendation to consider the use of a leukotriene receptor antagonist is extrapolated from the 2016 revision of the ARIA international guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek, 2017</a>] and expert opinion in the BSACI guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>] and in the European position paper [<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>].<ul><li>The ARIA guideline notes that some people with seasonal allergic rhinitis and asthma (especially exercise-induced disease) may benefit from a leukotriene receptor antagonist if they have ongoing symptoms, based on moderate-quality evidence.</li><li>The BSACI guideline cites limited evidence that these agents may have a role for people with refractory seasonal allergic rhinitis symptoms who also have a history of asthma, in addition to an oral or topical antihistamine.</li><li>The European position states that montelukast monotherapy is effective in both seasonal and perennial allergic rhinitis in two small studies in children.</li></ul></li></ul><h5>Prescribing oral corticosteroids for severe refractory symptoms</h5><ul><li>The recommendation to consider prescribing a short course of oral corticosteroids for severe refractory rhinitis symptoms is based on the 2010 revision of the ARIA international guideline which found very low-quality evidence to support this approach. It recommends this treatment for a few days as a 'last resort' when combinations of other treatments are ineffective [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brozek et al, 2010</a>].</li><li>The BSACI guideline notes there is no consensus in the literature on the optimal dose and duration of oral corticosteroid treatment, but suggests a dose for adults of 0.5 mg/kg in the morning, for 5–10 days. It also advises the person to continue using an intranasal corticosteroid preparation, to allow optimal intranasal cavity drug penetration [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>].</li><li>The recommended oral corticosteroid doses for children are based on the European position paper, which suggests a short course of 10–15 mg of prednisolone for 3–7 days for school-age children [<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>].</li></ul><h5>Advice on durations of drug treatment</h5><ul><li>The information on the timings of likely exposure to causative allergens is extrapolated from information in the 2008 ARIA international guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">ARIA, 2008</a>].</li><li>The recommendation to start intranasal corticosteroids two weeks prior to a known allergen season is based on the fact that the maximal effect of intranasal corticosteroids may not be seen until two weeks after starting treatment [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>].</li></ul><h5>Arranging specialist referral</h5><ul><li>The recommendations to consider referral to an ear, nose, and throat (ENT) specialist if there are red flag symptoms or structural abnormalities are based on expert opinion in the BSACI guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Scadding, 2017</a>] and in the European position paper [<a class="bibliography-reference internal-reference" href="../../references/index.html">Roberts, 2013</a>], as nasendoscopy may allow visualisation of the posterior nasal cavity and middle meatus. This is supported by expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Barr, 2014</a>].</li><li>The recommendation to consider referral to an allergy specialist for possible allergy testing to identify specific allergen triggers which can then be avoided and possible immunotherapy, is based on an expert consensus statement [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lipworth, 2017</a>] and expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Saleh, 2007</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Barr, 2014</a>]. Interestingly, the expert consensus statement notes that the majority of people with allergic rhinitis in primary care can be managed without formal identification of the specific allergen trigger.</li></ul><!-- end field 6e38b8aa-27a0-4de5-a606-6586514e41c2 --><!-- end item f2d59e43-7d9e-486b-a7c8-ba015468d97c --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/allergic-rhinitis/management/management/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>